Ann Hunter-Van Kirk

And quality is so important.

Is that, you know, how did you weigh the decision to manufacture in the U.S.

when obviously so many people choose international locations from a cost perspective?

Fantastic.

Maybe let's think about the commercial launch.

You received approval, of course, last August.

I know you've done some co-promotion and there are certainly regional dynamics.

You're now approved across the world.

Talk us through the commercial launch in this market.

Fantastic.

And the direct-to-consumer market is, of course, receiving a lot of attention now with an increase in the untitled FDA letters.

From your perspective, and the US is, of course, one of the only places where direct-to-consumer is allowed.

From your perspective, how does that kind of change marketing in the rest of the world for you?

Certainly, certainly.

And the I know the allergies, of course, are increasing across the US and young children.

And I know you've done a lot partnering with schools.

Can you tell us about those efforts and how you you work with schools there?

That's fantastic.

All right.

And so just thinking, you know, as you've created this incredible drug, a new administration that is beneficial, certainly to a pediatric population, as well as everyone else.